China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine Co., Ltd (SHE: 000963), expanding their strategic partnership initially formed in November 2020. The agreement focuses on the co-development of innovative bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), marking a significant step forward in their collaborative efforts.
Huadong Medicine’s Diverse Business Lines
Founded in 1993, Huadong Medicine has established a strong presence across four distinct business lines: pharmaceutical industry, pharmaceutical commerce, medical aesthetics, and industrial microbiology. The company’s diverse portfolio positions it as a key player in the pharmaceutical sector, with a broad range of expertise and capabilities.
Sanyou Bio’s Integrated 4C Business System
Sanyou Bio, established in 2015, is dedicated to creating a 4C business system that integrates differentiated CRO (Contract Research Organization), integrated CDO (Contract Development and Manufacturing Organization), collaborative CPO (Contract Production Organization), and distinctive CRS (Contract Research and Services). This comprehensive approach allows Sanyou Bio to offer a wide range of services and solutions in the biopharmaceutical industry.
Expanding Collaboration in Biopharmaceutical Innovation
The licensing deal between Sanyou Biopharmaceuticals and Huadong Medicine Co., Ltd signifies the expansion of their strategic partnership, aimed at developing cutting-edge macromolecule therapeutic products. This collaboration combines Huadong Medicine’s extensive experience with Sanyou Bio’s innovative 4C business system, creating a strong foundation for the development of novel BsAbs and ADCs.-Fineline Info & Tech
